Revenue and Profit Growth - Revenue for the third quarter reached 389.55 million yuan, a year-on-year increase of 49.11%[2] - Net profit attributable to shareholders of the listed company was 109.55 million yuan, up 23.38% year-on-year[2] - Total operating revenue for the first three quarters of 2024 reached 1,075,267,105.77 RMB, a significant increase from 668,099,047.91 RMB in the same period of 2023[14] - Net profit attributable to the parent company's shareholders for the first three quarters of 2024 was 913,270,453.15 RMB, up from 647,181,036.71 RMB in the same period of 2023[13] - Total profit for the period was RMB 361.83 million, an increase from RMB 277.23 million in the previous period[15] - Net profit attributable to the parent company's shareholders was RMB 317.59 million, up from RMB 251.97 million[15] - Basic earnings per share (EPS) increased to RMB 1.68 from RMB 1.33[15] R&D and Operating Expenses - R&D investment for the quarter was 39.93 million yuan, accounting for 10.25% of revenue, a decrease of 2.11 percentage points year-on-year[2] - R&D expenses for the first three quarters of 2024 amounted to 77,654,725.68 RMB, up from 64,674,073.63 RMB in the same period of 2023[14] - Sales expenses for the first three quarters of 2024 were 150,875,501.68 RMB, compared to 126,933,548.78 RMB in the same period of 2023[14] - Operating costs for the first three quarters of 2024 were 720,300,574.45 RMB, compared to 402,850,711.88 RMB in the same period of 2023[14] Assets and Liabilities - Total assets as of the end of the reporting period were 3.41 billion yuan, an increase of 11.24% compared to the end of the previous year[3] - The company's equity attributable to shareholders of the listed company was 2.33 billion yuan, up 9.42% from the end of the previous year[3] - Total assets as of Q3 2024 were 3,406,015,585.20 RMB, an increase from 3,061,786,608.56 RMB in the previous year[12] - Fixed assets increased to 1,387,928,661.32 RMB in Q3 2024, up from 1,088,802,327.00 RMB in the previous year[12] - Long-term loans rose to 547,497,926.78 RMB in Q3 2024, compared to 258,532,806.61 RMB in the previous year[13] - Total liabilities as of Q3 2024 were 863,139,790.82 RMB, up from 705,851,951.24 RMB in the previous year[13] Cash Flow and Financial Activities - Operating cash flow for the first three quarters was 217.06 million yuan, a significant increase of 65.99% year-on-year[2] - Net cash flow from operating activities was RMB 217.06 million, up from RMB 130.77 million[17] - Net cash flow from investing activities was negative RMB 597.13 million, compared to positive RMB 125.10 million in the previous year[18] - Net cash flow from financing activities was positive RMB 114.50 million, compared to negative RMB 53.95 million[18] - Total cash and cash equivalents at the end of the period were RMB 266.23 million, down from RMB 552.00 million[18] - Cash received from sales of goods and services was RMB 1,006.01 million, compared to RMB 658.87 million in the same period last year[17] - Cash paid for the purchase of goods and services was RMB 290.48 million, up from RMB 154.35 million[17] - Cash paid for the construction of fixed assets, intangible assets, and other long-term assets was RMB 284.24 million, compared to RMB 182.60 million[17] Shareholder and Equity Information - The company's total share capital increased from 105,250,992 shares at the beginning of the period to 189,544,528 shares at the end of the period[11] - The largest shareholder, Jie Jiangbing, holds 24,490,410 shares, accounting for 12.92% of the total shares[8] - Beijing Bojian Hechuang Technology Co., Ltd. holds 10,926,407 shares, accounting for 5.76% of the total shares[8] - Bai Ying holds 10,662,746 shares, accounting for 5.63% of the total shares[8] Financial Position and Performance Metrics - The company's basic earnings per share for the quarter were 0.58 yuan, a 23.40% increase year-on-year[2] - Weighted average return on equity (ROE) for the quarter was 4.74%, an increase of 0.36 percentage points year-on-year[2] - The company's revenue growth was driven by sustained growth in surgical treatment and myopia control businesses, as well as rapid growth in vision care business[6] - Operating profit for the first three quarters of 2024 was 363,056,896.70 RMB, compared to 277,234,392.29 RMB in the same period of 2023[14] Asset and Liability Changes - The company's monetary funds decreased from 536,658,290.19 RMB to 271,078,313.67 RMB[11] - The company's accounts receivable increased from 212,818,441.20 RMB to 386,231,641.63 RMB[11] - The company's inventory increased from 181,350,575.21 RMB to 247,963,387.33 RMB[11] - The company's trading financial assets increased significantly from 20,122,739.73 RMB to 198,171,961.25 RMB[11] - The company's prepayments slightly increased from 29,422,681.29 RMB to 30,260,973.37 RMB[11] - The company's other receivables decreased from 6,033,624.30 RMB to 4,480,013.42 RMB[11] Government Subsidies and Non-Recurring Gains - Government subsidies received during the quarter amounted to 5.37 million yuan, contributing to non-recurring gains[4]

10月24日，由证券时报主办的第十八届中国上市公司价值评选获奖名单隆重揭晓，爱博医疗(688050)获 评"科创板上市公司价值30强"，董事长解江冰博士获评"中国上市公司年度科创先锋人物"。 作为创新驱动的眼科医疗器械制造商，爱博医疗的产品涵盖眼科手术治疗、近视防控和视力保健三大领 域，全力为白内障手术、屈光不正矫正和视光消费提供一站式解决方案。 在手术治疗领域，公司专注于开发应用在白内障手术的中高端医疗器械，核心手术产品为自主研发、多 个价位可供选择的"普诺明"等系列基础及功能性人工晶状体。 在近视防控领域，公司专注于开发近视防控产品及配套的日常护理产品，核心近视防控产品是"普诺 瞳"品牌的角膜塑形镜，同时开发了离焦镜和日用硬性接触镜，与角膜塑形镜形成互补，为患者提供更 多选择，以满足不同的近视控制需求。 在视力保健领域，公司专注于开发近视矫正产品及配套的日常护理产品，核心产品是"澜柏""奥克 拉""TOPPOP"等品牌的透明隐形眼镜（蓝片）、彩色隐形眼镜（彩片）并提供产品代工服务。 本次公司获评科创板30强及年度科创先锋人物，体现了主流市场对于公司成长性的高度认可。 公司研发的"普诺明"非球面人工晶状体打 ...

医药生物 证 券 研 究 报 告 上 市 公 司 公 司 研 究/ 公 司 点 评 2024 年 09 月 09 日 爱博医疗 (688050) ——2024H1 业绩符合预期，看好公司多轮驱动高增长 | --- | --- | |-----------------------------|-------------------------------| | 市场数据： | 2024 年 09 月 09 日 | | 收盘价（元） | 77.50 | | 一年内最高/最低（元） | 198.47/65.17 | | 市净率 | 6.5 | | 息率（分红/股价） | 0.63 | | 流通 A 股市值（百万元） | 14,690 | | 上证指数/深证成指 | 2,736.49/8,063.27 | | --- | --- | |-------------------------------|-------------------------------| | | | | | | | 基础数据 : | 2024 年 06 月 30 日 | | | 11.90 | | 每股净资产（元） | | | 资产负债率 % ...

证券研究报告 | 2024年09月09日 爱博医疗（688050.SH） 优于大市 二季度收入同比增长 73%，人工晶体及隐形眼镜业务增长亮眼 二季度收入增长强劲，隐形眼镜业务利润率未达稳态。2024 年上半年公司实 现营收 6.86 亿（+68.54%），归母净利润 2.08 亿（+27.49%），扣非归母净 利 1.99 亿（+29.95%）。单二季度实现营收 3.75 亿（+72.91%），环比增长 20.91%，为连续环比增长的第 6 个季度，单季度营收达到历史最高水平，归 母净利 1.05 亿（+24.01%），扣非归母净利 1.00 亿（+28.26%）。公司收入 强劲增长，但隐形眼镜业务处于产能扩张期，各项成本偏高，利润率尚未达 到稳态，因此影响整体净利增速。 人工晶体及隐形眼镜业务增长亮眼。分具体业务看，手术治疗产品中，"普 诺明"等系列人工晶体收入 3.19 亿（+30.20%），受益于集采中标和勾选良 好、多焦人工晶体逐步开拓市场，销量保持快速增长。近视防控产品中，"普 诺瞳"角膜塑形镜收入 1.13 亿（+6.89%），角膜塑形镜业务受消费降级、 竞品增加等因素影响，市场增速有所放缓，公 ...

证券代码：688050 证券简称：爱博医疗 爱博诺德（北京）医疗科技股份有限公司 投资者关系活动记录表 编号：202409－01 | --- | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------------|-----------------| | | | | | | | □特定对象调研 | □分析师会议 □媒体采访 | | | 投资者关系活动 | □业绩说明会 □新闻发布会 | | □路演活动 | | 类别 | □现场参观 | 其他（电话会议） | | | | | 朱雀基金、中再资管、中域投资、中邮证券、中邮创业基金、 | | | | | 中英人寿保险、中银基金、中信证券、中信建投、中泰证券资 | | | | | 管、中融汇信投资、中欧瑞博投资、中粮期货、中海基金、中 | | | | | 国守正基金、中国人寿资管、中国人寿养老保险、中国人保资 | | | | | 管、中庚基金、致顺投资、知合、正圆私募基金、真脉、浙商 | | | | ...

总股本（万股） 18,954.45 2024 年 08 月 27 日 公司研究 评级：买入(维持) 研究所： 证券分析师： 李明 S0350523090001 lim06@ghzq.com.cn [Table_Title] 多焦晶体拓开市场，隐形眼镜业务增收减亏 ——爱博医疗（688050）2024 年半年报点评 最近一年走势 事件: 爱博医疗于 8 月 22 日发布 2024 年半年度报告：2024 年上半年，公司实 现收入 6.86 亿元（+69%，同比口径，下同）、归母净利润 2.08 亿元 （+27%）、扣非归母净利润 1.99 亿元（+30%）。 投资要点: 受益于集采中标和多焦晶体拓开市场，人工晶状体业务表现亮眼。 2024 年上半年，公司多业务条线保持强劲增长，其中人工晶状体收 入 3.19 亿元（+30%），其他手术产品收入 0.13 亿元（+38%）。公 司人工晶状体集采中标和勾选良好，在市场的受欢迎程度高于进口 晶体；医院开户数角度，截至 2024 年年中，公司人工晶状体已覆盖 全国 3500 多家医院，相较 2023 年底 3200 多家增加了 300 家左右。 相对沪深 300 表现 ...

证券研究报告 非金融公司|公司点评|爱博医疗（688050） 人工晶体和隐形眼镜表现亮眼 请务必阅读报告末页的重要声明 glzqdatemark1 2024年08月24日 证券研究报告 |报告要点 公司披露 2024 年半年报，实现营收 6.86 亿元，同比增长 68.54%；归母净利润 2.08 亿元，同 比增长 27.49%；扣非归母净利润 1.99 亿元，同比增长 29.95%；单 Q2 实现营收 3.75 亿元， 同比增长 72.91%；归母净利润 1.05 亿元，同比增长 24.01%；扣非归母净利润 1.00 亿元，同 比增长 28.26%，主要由于人工晶体和隐形眼镜放量驱动业绩高增长。 |分析师及联系人 郑薇 SAC：S0590521070002 请务必阅读报告末页的重要声明 1 / 5 非金融公司|公司点评 glzqdatemark2 2024年08月24日 爱博医疗(688050) 人工晶体和隐形眼镜表现亮眼 | --- | --- | --- | |--------------------|-----------------|-------------------------------- ...

| --- | --- | |--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | 证券研究报告 ...

证券研究报告·公司点评报告·医疗器械 爱博医疗（688050） 2024 年 H1 业绩点评：收入超我们预期，看 好长期成长性 2024 年 08 月 22 日 买入（维持） | --- | --- | --- | --- | --- | --- | |------------------------------|--------|--------|----------|----------|----------| | 盈利预测与估值 [Table_EPS] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业总收入（百万元） | 579.50 | 951.18 | 1,350.18 | 1,817.36 | 2,441.28 | | 同比（ % ） | 33.81 | 64.14 | 41.95 | 34.60 | 34.33 | | 归母净利润（百万元） | 232.69 | 303.98 | 402.70 | 530.85 | 724.94 | | 同比（ % ） | 35.80 | 30.63 | 32.48 | 31.82 | 36.56 | | EPS- 最 ...

开源证券 医药生物/医疗器械 公 司 研 究 爱博医疗（688050.SH） 2024 年 08 月 22 日 2024 上半年业绩快速增长，隐形眼镜业务超预期增 长 投资评级：买入（维持） ——公司信息更新报告 +68.54%，下文都是同比口径）， 1.99 亿元（+29.95%），毛 -9.94pct）。2024 年上半年公司人工 晶体及隐形眼镜板块增长超预期，我们看好公司的长期发展，维持公司的盈利预 2024-2026 4.03/5.24/6.67 亿元，当前股价对应 PE 为 35.8/27.6/21.6 倍，维持"买入"评级。 | --- | --- | --- | --- | |--------------------------|-------------------|--------------------------------------|--------------------------------------------------| | 日期 \n当前股价 ( 元 ) | 2024/8/21 \n76.14 | 余汝意（分析师） \nyuruyi@kysec.cn | 阮帅（分析师 ...